2. Signaling Pathways
  3. Immunology/Inflammation
  4. PD-1/PD-L1

PD-1/PD-L1

PD-1/Programmed death-ligand 1

PD-1/PD-L1

Related Products

PDF 0.7 MB

Programmed death-1 (PD-1) is a cell surface receptor that functions as a T cell checkpoint and plays a central role in regulating T cell exhaustion. PD-1 is activated by the engagement of its ligands PDL-1 or PDL-2. PD-1 receptor delivers inhibitory checkpoint signals to activated T cells upon binding to its ligands PD-L1 and PD-L2 expressed on antigen-presenting cells and cancer cells, resulting in suppression of T-cell effector function and tumor immune evasion. Inhibiting the programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) pathway is an attractive strategy for tumor immunotherapy.

PD-1 is expressed on activated T cells, B cells, monocytes, dendritic cells (DCs), regulatory T cells (Tregs), and natural killer T cells (NKT). It is a member of a family of immunoglobulin domain (Ig) co-receptors that modify the outcome of activation of the T cell receptor by an antigen-presenting cell (APC) or infected target cell. PD-L1 is widely and constitutively expressed on both hematopoietic and nonhematopoietic cells; e.g., naive T and B cells, vascular endothelial cells, and pancreatic islet cells, whereas PD-L2 is exclusively and inducibly expressed on professional APCs.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-174830
    GJ19
    		Inhibitor
    GJ19 is a PD-L1 inhibitor with an IC50 of 32.06 nM. GJ19 can effectively bind to human/murine PD-L1 protein with KD values of 171 and 290 nM, respectively. GJ19 concentration-dependently promotes HepG2 cell mortality in a co-culture model of HepG2/hPD-L1 and Jurkat T/hPD-1 cells. GJ19 effectively suppresses tumor growth in a B16-F10 melanoma mouse model. GJ19 can be used for the study of tumor immunotherapy.
    GJ19
  • HY-120402
    BMS-200
    		Inhibitor
    BMS-200 is a potent PD-1/PD-L1 interaction inhibitor with an IC50 of 80 nM. BMS-200 can induce dimerization of PD-L1.
    BMS-200
  • HY-P990623
    MDX-1105
    		Inhibitor ≥99.0%
    MDX-1105 is a human antibody expressed in CHO that targets B7-H1/PD-L1/CD274. MDX-1105 has a huIgG4SP type heavy chain, and its predicted molecular weight (MW) is 150 kDa. The isotype control for MDX-1105 can be referenced as Human IgG4 kappa, Isotype Control (HY-P99003).
    MDX-1105
  • HY-W457085
    PD-1/PD-L1-IN-29 intermediate-2
    PD-1/PD-L1-IN-29 intermediate-2 is an intermediate of PD-1/PD-L1 inhibitors and can be used to synthesize Antibody-Drug Conjugates (ADCs).
    PD-1/PD-L1-IN-29 intermediate-2
  • HY-164476
    ES-072
    		Activator 98.05%
    ES-072 is an orally effective selective EGFR mutant (EGFR-T790M) inhibitor. ES-072 activates GSK3α by inhibiting EGFR-T790M activity, which promotes phosphorylation of PD-L1 at Ser279 and Ser283. The phosphorylated PD-L1 recruits the E3 ubiquitin ligase ARIH1, leading to ubiquitination and proteasomal degradation of PD-L1. This mechanism not only reduces cancer cell growth but also enhances anti-tumor immune response by lowering PD-L1 levels. ES-072 can be used to inhibit proliferation in non-small cell lung cancer (NSCLC) cells.
    ES-072
  • HY-P991209
    Nebratamig
    		Inhibitor
    Nebratamig (GNC-035) is an anti-ROR1/anti-CD3/anti-PD-L1/anti-4-1BB tetra-specific antibody with potential immunostimulatory and antineoplastic activities.
    Nebratamig
  • HY-P99714
    Lorigerlimab
    		Inhibitor
    Lorigerlimab (MGD019) is a bispecific IgG4 dual-affinity re-targeting antibody (DART). Lorigerlimab can block PD-1 and CTLA-4, and improves T-cell responses. Lorigerlimab can be used for research of metastatic castration-resistant prostate cancer (mCRPC).
    Lorigerlimab
  • HY-P990114
    Anti-Canine PD-L1/B7-H1 Antibody (JC071)
    		Inhibitor
    Anti-Canine PD-L1/B7-H1 Antibody (JC071) is an anti-canine PD-L1/B7-H1 IgG1 monoclonal antibody. Anti-Canine PD-L1/B7-H1 Antibody (JC071) can specifically bind to CHO-PDL1 cells and K562-cCD20-cPD-L1 cells. Anti-Canine PD-L1/B7-H1 Antibody (JC071) can enhance the level of IFN-γ. Anti-Canine PD-L1/B7-H1 Antibody (JC071) is often used in western blot experiments.
    Anti-Canine PD-L1/B7-H1 Antibody (JC071)
  • HY-101098
    PD-1-IN-18
    		Inhibitor
    PD-1-IN-18 is a PD1 signaling pathway inhibitor, which acts as an immunomodulator.
    PD-1-IN-18
  • HY-101097A
    PD-1-IN-17 TFA
    		Inhibitor
    PD-1-IN-17 TFA is a programmed cell death-1 (PD-1) inhibitor extracted from patent WO2015033301A1, Compound 12, inhibits 92% splenocyte proliferation at 100 nM.
    PD-1-IN-17 TFA
  • HY-103048
    PD-1/PD-L1-IN 3
    		Inhibitor
    PD-1/PD-L1-IN 3, a macrocyclic peptide, is a potent and selective inhibitor of the PD-1/PD-L1 and CD80/PD-L1 interactions extracted from patent WO2014151634A1, compound No.1. PD-1/PD-L1-IN 3 interferes with PD-L1 binding to PD-1 and CD80 by binding to PD-L1, with IC50s of 5.60 nM and 7.04 nM, respectively. PD-1/PD-L1-IN 3 can be used for the research of various diseases, including cancer and infectious diseases.
    PD-1/PD-L1-IN 3
  • HY-100022A
    Tomivosertib hydrochloride
    		Inhibitor
    Tomivosertib hydrochlorideis a potent, highly selective, and orally active MNK1 and MNK2 inhibitor, with IC50s of 1-2 nM against both isoforms. Tomivosertib hydrochloride treatment leads to a dose-dependent reduction in eIF4E phosphorylation at serine 209 (IC50=2-16 nM) in tumor cell lines. Tomivosertib hydrochloride also dramatically downregulates PD-L1 protein abundance.
    Tomivosertib hydrochloride
  • HY-101093B
    PD-1-IN-20
    		Inhibitor
    PD-1-IN-20 is the less active enantiomer of PD-1-IN-1. PD-1-IN-1 is an inhibitor of programmed cell dealth-1 (PD-1) extracted from patent WO 2015033299 A1, compound example 4.
    PD-1-IN-20
  • HY-16141R
    Cilengitide (Standard)
    		Inhibitor
    Cilengitide (Standard) is the analytical standard of Cilengitide. This product is intended for research and analytical applications. Cilengitide (EMD 121974) is a potent integrins antagonist with IC50s of 0.61 nM (ανβ3), 8.4 nM (ανβ5) and 14.9 nM (α5β1), respectively. Cilengitide inhibits the binding of ανβ3 and ανβ5 to Vitronectin with IC50s of 4 nM and 79 nM, respectively. Cilengitide inhibits TGF-β/Smad signaling, mediates PD-L1 expression. Cilengitide also induces apoptosis, shows antiangiogenic effect in the research against glioblastoma and other cancers.
    Cilengitide (Standard)
  • HY-N2907R
    Atranorin (Standard)
    		Inhibitor
    Atranorin (Standard) is the analytical standard of Atranorin (HY-N2907). This product is intended for research and analytical applications. Atranorin is a secondary metabolite of lichens and AKT inhibitor. Atranorin possesses multiple activities such as antibacterial, anti-inflammatory, antioxidant, anti-glycation, analgesic, and anti-tumor effects. Atranorin has IC50 values for scavenging DPPH and ABTS free radicals of 117 μM and less than 10 μM, respectively. Additionally, Atranorin also exhibits effects in promoting wound healing. Atranorin can be used in the research of various diseases, including myelodysplastic syndromes, tumors, and inflammatory conditions.
    Atranorin (Standard)
  • HY-P99499
    Cetrelimab
    		Inhibitor ≥99.0%
    Cetrelimab (JNJ 63723283; JNJ 3283) is a human IgG4κ mAb targeting PD-1. Cetrelimab binds PD-1 (Kd=1.72 nM, HEK293) to block the interaction of PD-1 with PD-L1 and PD-L2 (IC50s=111.7 ng/mL and 138.6 ng/mL, respectively). Cetrelimab stimulates peripheral T cells, increases IFN-γ, IL-2, TNF-α level and inhibits tumor growth in vivo.
    Cetrelimab
  • HY-P99799
    Pacmilimab
    		Inhibitor
    Pacmilimab (CX-072) is a potent PD-L1 inhibitor. Pacmilimab shows antitumor activity.
    Pacmilimab
  • HY-P99106
    Acrixolimab
    		Inhibitor
    Acrixolimab a humanized IgG4-κ antibody, targeting to PD-1.
    Acrixolimab
  • HY-B0008A
    Sulindac sodium
    		Modulator
    Sulindac (MK-231) is an orally active nonsteroidal anti-inflammatory agent. Sulindac also is an immunomodulatory agent. Sulindac can be used for the research of arthritis of the spine, gouty arthritis and kinds of cancer including colorectal cancer (CRC) and lung cancer.
    Sulindac sodium
  • HY-P990757
    Ragistomig
    Ragistomig is an anti-TNFRSF9/CD274 IgG1 monoclonal antibody composed of a κ light chain and a variable region with a λ light chain and an IgG1 heavy chain. The overall structure is a dimer composed of two identical IgG1 heavy chains.
    Ragistomig
Cat. No. Product Name / Synonyms Application Reactivity